GBCI
Glacier Bancorp, Inc.
GBCI has the edge over MS overall, supported by stronger valuation and stronger fundamentals.
MS
Morgan Stanley
MS has slightly lower modeled downside risk, despite its lower overall score.
GBCI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
GBCI's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like GBCI.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
GBCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $48.14 | — |
| Cheap | 15x | $41.07 | -15% |
| Current | 18x | $48.14 | — |
| Fair | 19x | $50.20 | +4.3% |
| Expensive | 24x | $63.13 | +31% |
Historical ranges are pointers, not guarantees.
GBCI has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
GBCI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for GBCI, with profitability improving.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
GBCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.48 | +30% |
| Q3 2026 | $2.67 | +31% |
| Q2 2026 | $2.44 | +27% |
| Q1 2026 | $2.14 | +15% |
| Q4 2025 | $1.99 | +19% |
| Q3 2025 | $2.04 | +26% |
| Q2 2025 | $1.92 | +17% |
| Q1 2025 | $1.86 | +6.3% |
| Q4 2024 | $1.67 | -17% |
GBCI earned $2.67 per share over the past year, up 31% from the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over GBCI on earnings, with more consistent year-over-year improvement.
GBCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $329.8M | +27% |
| Q2 2026 | $317.5M | +32% |
| Q1 2026 | $306.8M | +38% |
| Q4 2025 | $306.5M | +37% |
| Q3 2025 | $260.7M | +21% |
| Q2 2025 | $240.6M | +21% |
| Q1 2025 | $222.6M | +13% |
| Q4 2024 | $223M | +13% |
GBCI has the edge over MS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | +7.6 points |
| Q2 2026 | 39% | +12 points |
| Q1 2026 | 33% | +4.1 points |
| Q4 2025 | 25% | -8.1 points |
| Q3 2025 | 33% | +3.8 points |
| Q2 2025 | 27% | -0.2 points |
| Q1 2025 | 29% | +10 points |
| Q4 2024 | 33% | +1.5 points |
GBCI has the edge over MS on profitability, with a higher operating margin.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
GBCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $149.8M | +43% |
| Q2 2026 | $111.7M | +40% |
| Q1 2026 | $74.4M | +59% |
| Q3 2025 | $104.8M | -30% |
| Q2 2025 | $79.5M | +27% |
| Q1 2025 | $46.8M | +$103.5M |
| Q3 2024 | $150.1M | +15% |
| Q2 2024 | $62.7M | -48% |
GBCI has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
GBCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +86.3K shares |
| 1 year | +10% | +11.8M shares |
| 3 years | +18% | +19.5M shares |
| 5 years | +36% | +34.8M shares |
| Available history | +48% | +42M shares |
GBCI has 130M diluted shares, up 10% from a year ago.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over GBCI on shareholder dilution, with a more favorable share count trend.
GBCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 3.6x | Elevated |
| Q1 2025 | 4.7x | High |
| Q4 2024 | 6.5x | High |
GBCI has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
GBCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.0 | Neutral |
| Stochastic | 66.4 | Neutral |
GBCI's weekly RSI is 53 (neutral) and its Stochastic is 66 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
GBCI PE vs Financial Services Sector
| Metric | GBCI | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 13x | 38% above |
| PE % | 39 | 63 | 24 pts below |
GBCI is trading at 18x earnings, a 38% premium to the Financial Services sector's median of 13x.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS has the edge over GBCI on valuation relative to its sector.
GBCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.0 | 4.7% above |
| 20 week MA | $47.7 | 0.9% above |
| 50 week MA | $47.4 | 1.5% above |
| 100 week MA | $46.4 | 3.8% above |
| 200 week MA | $42.7 | 13% above |
GBCI has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
GBCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $45.9 | $45.9 | -0.1% |
| 2021 | $45.9 | $56.0 | +22% |
| 2022 | $56.0 | $49.3 | -12% |
| 2023 | $49.3 | $41.3 | -16% |
| 2024 | $41.3 | $50.3 | +22% |
| 2025 | $50.3 | $45.5 | -9.5% |
| 2026 YTD | $45.5 | $48.1 | +5.8% |
GBCI has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.